Clinical Advisory Board

Michael J Overman, MD
Michael J Overman, MD
Professor, The University of Texas MD Anderson Cancer Center, Houston, TX; Committee Vice Chair, The University of Texas MD Anderson Cancer Center - ECMS, Houston, TX

Dr. Michael Overman is a Professor of Gastrointestinal Medical Oncology and Chair at the University of Texas MD Anderson Cancer Center Executive Committee of the Medical Staff, Houston, TX. He is also the Cancer Medicine Executive Director for the Cancer Network.

Dr. Overman received his medical degree from Johns Hopkins School of Medicine. He did his Internal Medicine training at Harbor UCLA and his Medical Oncology/Hematology fellowship at MD Anderson Cancer Center. He joined the faculty at MD Anderson Cancer Center in 2007. He served as Committee Chair, The University of Texas MD Anderson Cancer Center, Pharmacy & Therapeutic Committee, Houston, TX, during the period of 2015 – 2018 and was the GI Symposium American Society of Clinical Oncology Merit Award Winner in 2007.

Dr. Overman’s research efforts have focused upon novel clinical trials in both pancreatic and intestinal cancers. In particular, he has been a principal investigator on a number of clinical trials investigating immune-checkpoint therapy in gastrointestinal malignancies.  He has ongoing efforts to investigate the role of stromal modulation to enhance the activity of immune-checkpoint therapy.

Wendy Levin, MD
Wendy Levin, MD
Chief Medical Officer, Biofidelity

Dr. Levin is a Hematologist and Oncologist with over 15 years of clinical drug development industry experience, spanning a broad range of early and late targets and disease indications. She completed her undergraduate and graduate studies at the University of California Los Angeles (UCLA, under the guidance of Dr. Dennis J. Slamon), and co-authored the first publications on HER-2/neu in breast and ovarian cancers. She completed her Internal Medicine residency at University of Southern California (LAC + USC), and her Fellowship at the University of Washington/Fred Hutchinson Cancer Research Center. As an Attending Physician University of Washington, she focused on malignant hematology and sarcoma. In her first Industry role at Pfizer, she led the development of the Pfizer Hedgehog inhibitor Daurismo from pre-clinical IND to designing the FDA Registration trial for Daurismo in elderly unfit acute myeloid leukemia (AML). She has since held increasingly responsible roles in both pharma and biotech,  and is the co-author of over 30 publications.

Cindy Ru, PhD
Cindy Ru, PhD
Founder and Managing Director, CRC Oncology

Dr. Qinhua Cindy Ru is the Managing Director of CRC Oncology, a contract research organization focused on reshaping the global landscape of innovative drugs and therapies for cancer treatment, especially in the field of advanced cell and gene therapy. Dr. Ru has over 20 years of global leadership experience in Oncology Clinical Research, Regulatory Filings, Product Launch, and Business Development in global pharmaceutical and biotech companies such as Pfizer (La Jolla, CA US), Novartis (East Hanover, NJ US), Merck (Upper Gwynedd, PA US), Sihuan (Beijing, China), and Exelixis (South San Francisco, CA US). Prior to founding CRC Oncology, she served as CSO and Executive Vice President at CARsgen Therapeutics, a biotech focused on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors.

Dr. Ru holds a PhD in Chemistry from Tsinghua University (Beijing, China) and completed her Post-Doctoral training at Los Alamos National Laboratory, Biosciences Division (Los Alamos, NM US).